Effect of Route of Administration on Drug Disposition

  • S. Riegelman
  • M. Rowland


An increasing body of information tends to support the hypothesis that drug effect, therapeutic or toxic, is more closely correlated with plasma concentration than dose (Levy, 1968). Absorption is one important determinant of drug plasma levels. Distribution and elimination are others. Most drugs are administered as drug products, not drug entities. The biologic performance of a drug product can be affected by its bioavailability (defined as a measure of the rate and extent to which a drug reaches a sampling site (usually a peripheral vein) or its site of action). Biophasic availability is generally reserved for situations where pharmacologic data are used to assess biologic performance (Smolen, 1971). This paper discusses the various factors that can influence the bioavailability of drug products. Major emphasis is placed on preparations intended for oral administration.


Dosage Form Drug Product Biliary Atresia Extraction Ratio Hepatic Clearance 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Ariens, E. J., 1968, Il Farmaco. Sci. Ed. 24: 1.Google Scholar
  2. Barr, W. H., 1969, Drug Information Bulletin, Jan./June, 27.Google Scholar
  3. Barr, W. H., Gerblach, L. A., Letcher, K., Plant, M., and Strahl, N., 1972, Clin. Pharmacol. and Therap. 13: 97.Google Scholar
  4. Barr, W. H., and Riegelman, S., 1970, J. Pharm. Sci. 59: 164.PubMedCrossRefGoogle Scholar
  5. Bischoff, K. B., and Dedrick, R. L., 1968, J. Pharm. Sci. 57: 1346.PubMedCrossRefGoogle Scholar
  6. Boyes, R. N., 1970, J. Pharmacol, and Exp. Therap. 174: 1.Google Scholar
  7. Boyes, R. N., Scott, D. B., Jebson, P. J., Godman, M. J., and Julian, D. G., 1971, Clin. Pharmacol. Therap. 12: 105.Google Scholar
  8. Boxenbaum, H., and Riegelman, S. (unpublished results).Google Scholar
  9. Brandt, J. L., Castelman, L., Rushkin, H. P., Greenwald, J., Kelly, J. J., Jr., and Jones, A., 1955, J. Clin. Invest. 34: 1017.PubMedCrossRefGoogle Scholar
  10. Crouthamel, W. G., Doluisio, J. T., Johnson, R. E., and Diamord, L. J., 1970, J. Pharm. Sci. 59: 878.PubMedCrossRefGoogle Scholar
  11. Davies, D. S., Morg, C. D., Connolly, M. E., Paterson, J. W., Sardler, M., and Dollery, C. T., 1970, Fed. Proc. 28: 797.Google Scholar
  12. Diczfalusy, E., and Levitz, M., 1970, in: Chemical and Biological Aspects of Steroid Conjugation (Bernstein, S. and Solomon, S., ed.), Springer-Verlag, Berlin.Google Scholar
  13. Dollery, C. T., Davies, D. S., and Connolly, M. E., 1971, Ann. N. Y. Acad. Sci. 179: 108.PubMedCrossRefGoogle Scholar
  14. Eger, F. I., 1962, in: Uptake and Distribution of Anesthetic Agents (E. M. Papper and R. J. Katz, ed.), McGraw-Hill Book Co., Inc., New York.Google Scholar
  15. Greenway, C. V., and Stark, R. D., 1971, Physiol. Rev. 51: 1.Google Scholar
  16. Kety, S. S., 1951, Pharmacol. Rev. 3: 1.PubMedGoogle Scholar
  17. Levy, G. 1968, in: Importance of Fundamental Principles in Drug Evaluation, p. 41 (D. H. Tedeschi and R. E. Tedeschi, eds.), Raven Press, New York.Google Scholar
  18. Lucas, G., Bridle, S. D., and Greengard, P., 1971, J. Pharmacol, and Exp. Therap. 178: 562.Google Scholar
  19. Lundquist, F., and Wolthers, M., 1958, Acta Pharmacol. Toxicol. 14: 267.Google Scholar
  20. McMahon, R. E., Ridolfo, A. S., Culp, H. W., Wolen, R. L., and Marshall, W. F., 1971, Toxicol. Appl. Pharmacol. 19: 427.PubMedCrossRefGoogle Scholar
  21. Perl, W., Rackow, H., Salantre, E., Wolf, G. L., and Epstein, R. M., 1965, Appl. Physiol. 20: 621.Google Scholar
  22. Portmann, G. A., 1970, in: Current Concepts in: Pharmaceutical Sciences-Biopharmaceutics (J. Swarbrick, ed.) Lea and Febiger, Philadelphia.Google Scholar
  23. Prescott, L. F., and Nimmo, L., 1971, J. Pharm. Exp. Therapy 128: 271.Google Scholar
  24. Rowland, M., 1973, in: Current Concepts in: the Pharmaceutical Sciences, Vol. II. Chapter 6. Biopharmaceutics (Swarbrick, J., ed.), Lea and Febiger, Philadelphia.Google Scholar
  25. Rowland, M., 1972, J. Pharm. Sci. 61: 70.PubMedCrossRefGoogle Scholar
  26. Rowland, M., Benet, L. Z., and Graham, G., 1973, J. Pharmacokin & Biopharm 1: 123, 1973.CrossRefGoogle Scholar
  27. Rowland, M., Riegelman, S., Harris, P. A., and Seholkoff, D., 1972, J. Pharm. Sci. 61: 379.PubMedCrossRefGoogle Scholar
  28. Riegelman, S., Loo, J. C. K., and Rowland, M., 1968, J. Pharm. Sci. 57: 117.PubMedCrossRefGoogle Scholar
  29. Sheline, R. R., 1968, J. Pharm. Sci. 57: 2021.CrossRefGoogle Scholar
  30. Shand, D. G., Cavanaugh, J. H., and Oates, J. A., 1972, Clin. Pharmacol. Therap. 12: 769.Google Scholar
  31. Shand, D., and Rangno, R. E., 1971, Pharmacol. 7: 159.CrossRefGoogle Scholar
  32. Sjoqvist, F., Alexanderson, B., Osberg, M., Bertillson, L., Borga, O., and Hamburger, B., 1971, Acta Pharmacol. Toxicol. 29: 255.CrossRefGoogle Scholar
  33. Stenson, R. E., Constantino, R. T., and Harrison, P. C., 1971, Circulation 43: 205.PubMedGoogle Scholar
  34. Ther, L., and Winne, D., 1971, Ann. Rev. Pharmacol. 11: 57.PubMedCrossRefGoogle Scholar
  35. Wagner, J. G., Welling, P. G., Roth, S. B., Sakmar, E., Lee, K. P., and Walker, J. E., 1971, Intern. J. Clin. Pharmacol. 5: 371.Google Scholar
  36. Wilkins, R. W., Culbertson, J. W., and Ingelfinger, F. J., 1951, J. Clin. Invest. 30: 312.PubMedCrossRefGoogle Scholar
  37. Winne, D., and Ochsenfahrt, H., 1967, J. Theoret. 14: 293.CrossRefGoogle Scholar
  38. Winne, D., and Remischorsky, J., 1970, J. Pharm, and Pharmacol. 22: 640.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1972

Authors and Affiliations

  • S. Riegelman
    • 1
  • M. Rowland
    • 1
  1. 1.Department of PharmacyUniversity of CaliforniaSan FranciscoUSA

Personalised recommendations